Results 31 to 40 of about 1,117 (238)

Assessment of Therapeutic Antibody Developability by Combinations of In Vitro and In Silico Methods.

, 2021
Although antibodies have become the fastest-growing class of therapeutics on the market, it is still challenging to develop them for therapeutic applications, which often require these molecules to withstand stresses that are not present in vivo.

core   +1 more source

Simultaneous affinity maturation and developability enhancement using natural liability-free CDRs

mAbs, 2022
Affinity maturation is often a necessary step for the development of potent therapeutic molecules. Many different diversification strategies have been used for antibody affinity maturation, including error-prone PCR, chain shuffling, and targeted ...
Andre A. R. Teixeira, Sara D’Angelo, M. Frank Erasmus, Camila Leal-Lopes, Fortunato Ferrara, Laura P. Spector, Leslie Naranjo, Esteban Molina, Tamara Max, Ashley DeAguero, Katherine Perea, Shaun Stewart, Rebecca A. Buonpane, Horacio G. Nastri, Andrew R. M. Bradbury   +14 more
doaj   +1 more source

Development of disulfide-stabilized Fabs for targeting of antibody-directed nanotherapeutics

mAbs, 2022
Antibody-directed nanotherapeutics (ADNs) represent a promising delivery platform for selective delivery of an encapsulated drug payload to the site of disease that improves the therapeutic index.
Melissa L. Geddie, Dmitri B. Kirpotin, Neeraj Kohli, Tad Kornaga, Bjoern Boll, Maja Razlog, Daryl C. Drummond, Alexey A. Lugovskoy   +7 more
doaj   +1 more source

Balancing the extremes for antibody developability: hydrophobic and electrostatic germline framework signatures for CDR-loop compensation

mAbs
Antibody therapeutics are a rapidly growing class of biopharmaceuticals, but concerns regarding potential developability issues persist. While complementarity-determining region (CDR) loops are imperative for antigen specificity and mutations are ...
Vera A. Spanke, Valentin J. Egger-Hoerschinger, Clarissa A. Seidler, Katharina B. Kroell, Vincent Wieser, Sabine Imhof-Jung, Benjamin Weiche, Alexander Bujotzek, Guy Georges, Klaus R. Liedl   +9 more
doaj   +1 more source

Metrization of Weakly Developable Spaces

Sultan Qaboos University Journal for Science, 2002
In this note, we present metrization of weak developability.
Abdul M. Mohamad
doaj   +1 more source

An end-to-end automated platform process for high-throughput engineering of next-generation multi-specific antibody therapeutics

mAbs, 2021
Next-generation multi-specific antibody therapeutics (MSATs) are engineered to combine several functional activities into one molecule to provide higher efficacy compared to conventional, mono-specific antibody therapeutics.
Norbert Furtmann, Marion Schneider, Nadja Spindler, Bjoern Steinmann, Ziyu Li, Ingo Focken, Joachim Meyer, Dilyana Dimova, Katja Kroll, Wulf Dirk Leuschner, Audrey Debeaumont, Magali Mathieu, Christian Lange, Werner Dittrich, Jochen Kruip, Thorsten Schmidt, Joerg Birkenfeld   +16 more
doaj   +1 more source

Carcinomas and Carcinoid Tumors of the Lungs and Bronchi in Children and Adolescents: The EXPeRT Recommendations

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Primary lung carcinomas and bronchial carcinoid tumors (BC) are very rare malignancies in childhood. While typical BC and mucoepidermoid carcinomas are mostly low‐grade, localized tumors with a more favorable prognosis than in adults, necessitating avoidance of overtreatment, adenocarcinomas of the lung are often diagnosed at advanced disease ...
Michael Abele, Calogero Virgone, Michaela Kuhlen, Sabine Irtan, Yves Reguerre, Malgorzata Krawczyk, Ewa Bien, Tal Ben‐Ami, Maja Cesen, Ricardo Lopez‐Almaraz, Andrea Ferrari, Gianni Bisogno, Dominik T. Schneider, Abbas Agaimy, Constantin Lapa, Hubert Ducou le Pointe, Rainer Claus, Catherine Daniel, Ines B. Brecht, Daniel Orbach   +19 more
wiley   +1 more source

Application of protein language models for antibody developability prediction

mAbs
Protein language models (PLMs) provide a powerful framework for learning sequence – property relationships in antibodies. However, their performance and reliability in real-world industrial antibody discovery pipelines remain underexplored.
Samad Amini, Yimin Huang, Mark Julian, Christina Palmer, Simone Sciabola, Ye Wang   +5 more
doaj   +1 more source

How can we discover developable antibody-based biotherapeutics?

Frontiers in Molecular Biosciences, 2023
Antibody-based biotherapeutics have emerged as a successful class of pharmaceuticals despite significant challenges and risks to their discovery and development.
Joschka Bauer, Joschka Bauer, Nandhini Rajagopal, Nandhini Rajagopal, Priyanka Gupta, Priyanka Gupta, Pankaj Gupta, Pankaj Gupta, Andrew E. Nixon, Sandeep Kumar, Sandeep Kumar   +10 more
doaj   +1 more source

European Standard Clinical Practice Guideline and EXPeRT Recommendations for the Diagnosis and Management of Gastroenteropancreatic Neuroendocrine Neoplasms in Children and Adolescents

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Pediatric gastroenteropancreatic neuroendocrine neoplasms (GEP‐NENs) are extremely rare and clinically heterogeneous. Management has largely been extrapolated from adult practice. This European Standard Clinical Practice Guideline (ESCP), developed by the EXPeRT network in collaboration with adult NEN experts, provides (adult) evidence ...
Michaela Kuhlen, Calogero Virgone, Antje Redlich, Michael Abele, Ricardo Lopez‐Almaraz, Tal Ben‐Ami, Ewa Bien, Gianni Bisogno, Maja Mazic Cesen, Andrea Ferrari, Malgorzata A. Krawczyk, Yves Reguerre, Dominik T. Schneider, Ines B. Brecht, Charlotte Rigaud, Bilgehan Yalcin, Rainer Claus, Christian Vokuhl, Constantin Lapa, Jörg Fuchs, Segolene Hescot, Thomas Walter, Julien Hadoux, Daniel Orbach   +23 more
wiley   +1 more source